Teva Pharmaceuticals, a U.S. affiliate of Israel-based Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced on Tuesday four data presentations for AUSTEDO(R) (deutetrabenazine) tablets and TV-46000/mdc-IRM.

These data will be presented at the American Psychiatric Association (APA) Annual Meeting held 21-25 May 2022 in New Orleans, Louisiana, and again virtually 7-10 June 2022.

Featured data at this year's APA Annual Meeting include findings from a study evaluating long-term treatment with AUSTEDO in postmenopausal women with tardive dyskenisia (TD), as well as two surveys examining the impact of TD on physical, psychological and social aspects of patients' lives. Teva will also showcase data on an innovative copolymer technology under license from MedinCell that controls the steady release of risperidone in TV-46000, a risperidone extended-release injectable suspension formulation.

'We are excited to be back at APA live and in person during Mental Health Awareness Month this year to continue compelling dialogue about unmet need across the mental health spectrum and Teva's role in helping to meet those needs,' said Denisa Hurtukova, MD, VP, head of North America Medical Affairs. 'Our evolving clinical program across diseases of the central nervous system and mental health conditions underscores our ongoing commitment to advancing science for real-world solutions for neurological and psychiatric disorders.'